Bristol-Myers Squibb Co EV/EBITDA
Data as of August 04, 2026
EV/EBITDA
12.18
Enterprise Value
$168.25B
EBITDA (TTM)
$13.81B
Sector
Pharmaceuticals
How It's Calculated
12.18 = $168.25B ÷ $13.81B
What This Means
Bristol-Myers Squibb Co's EV/EBITDA of 12.2 is in a moderate range for Pharmaceuticals.
About Bristol-Myers Squibb Co
Bristol-Myers Squibb Co (BMY) operates in the Pharmaceuticals sector, specifically in Pharmaceuticals. With a market capitalization of about $133.41B, it ranks as a large-cap stock — a major established company.
Shares recently traded near $65.47, within a 52-week range of $42.52 to $65.66 (-0.3% from the high, +54.0% from the low). Beta of 0.23 indicates relatively lower volatility versus the market.
Trailing profit margin is about 12.3%, signaling a solid profit margin for its industry.
Understanding This Metric
EV/EBITDA is widely used when comparing companies with different debt loads because enterprise value includes net debt while EBITDA approximates operating cash earnings power. For Bristol-Myers Squibb Co, the ratio should be read with growth, capex needs, and cycle position in Pharmaceuticals. Pair EV/EBITDA with free cash flow yield and net debt metrics before drawing conclusions — especially when EBITDA is depressed or boosted by one-time items.
Using This Number in Practice
Near 12.18x EV/EBITDA, Bristol-Myers Squibb Co (BMY) carries a mid-range EV/EBITDA multiple that investors often stack-rank within the sector. Enterprise value of about $168.25B and EBITDA near $13.81B form the ratio — adjust for one-time items before treating the headline multiple as comparable.
Credit and LBO workflows often sort names on EV/EBITDA before drilling into free cash flow and maintenance capex. Pair this view with the EV/EBITDA calculator and the BMY metrics hub for related valuation pages.
Sector Comparison
Among Pharmaceuticals names on our S&P 100 coverage, Bristol-Myers Squibb Co's EV/EBITDA of 12.18 can be compared with peers such as LLY (31.82), JNJ (20.24), MRK (24.45). Sector context helps interpretation, but each company's growth profile and balance sheet differ — use multiple metrics before drawing conclusions. View all Pharmaceuticals stocks.
Key Takeaways
- BMY is grouped in the Pharmaceuticals sector for peer comparisons.
- Recent beta of 0.23 suggests lower-than-market price sensitivity.
- Trailing profit margin of 12.3% provides context for how much earnings support the headline multiple.
Related Tools & Guides
Explore calculators and guides connected to this metric, or view all metrics for BMY.
Learn the full workflow
Compare PE with PB, PEG, EV/EBITDA, and market cap in one structured path.
Open the Stock Valuation hub →Other BMY Metrics
Frequently Asked Questions
What is BMY's EV/EBITDA?
EV/EBITDA compares enterprise value to operating earnings before interest, taxes, depreciation, and amortization. Bristol-Myers Squibb Co's ratio is about 12.18 — common for comparing leveraged companies in Pharmaceuticals.
Is 12.18 high or low vs peers?
Among Pharmaceuticals peers (e.g. LLY (31.82), MRK (24.45), JNJ (20.24)), BMY's 12.18 should be read with growth, capex, and debt levels.
When is EV/EBITDA misleading?
EBITDA ignores capex, working capital, and stock-based comp; negative or tiny EBITDA makes the ratio meaningless. Cross-check with free cash flow and net debt.
Calculate the ev/ebitda for any stock with our free calculator.
Open EV/EBITDA Calculator →